Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 61

1.

The gut microbiome in tuberculosis susceptibility and treatment response: guilty or not guilty?

Eribo OA, du Plessis N, Ozturk M, Guler R, Walzl G, Chegou NN.

Cell Mol Life Sci. 2019 Nov 15. doi: 10.1007/s00018-019-03370-4. [Epub ahead of print] Review.

PMID:
31729564
2.

Evaluation of the effect of long-term use of antidepressants in the SSRI group on bone density with dental volumetric tomography.

Agacayak KS, Guler R, Ilyasov B.

Drug Des Devel Ther. 2019 Oct 3;13:3477-3484. doi: 10.2147/DDDT.S216822. eCollection 2019.

3.

Optimal composition and position of histidine-containing tags improves biodistribution of 99mTc-labeled DARPin G3.

Vorobyeva A, Schulga A, Konovalova E, Güler R, Löfblom J, Sandström M, Garousi J, Chernov V, Bragina O, Orlova A, Tolmachev V, Deyev SM.

Sci Rep. 2019 Jun 28;9(1):9405. doi: 10.1038/s41598-019-45795-8.

4.

Comparison of tumor‑targeting properties of directly and indirectly radioiodinated designed ankyrin repeat protein (DARPin) G3 variants for molecular imaging of HER2.

Vorobyeva A, Sсhulga A, Konovalova E, Güler R, Mitran B, Garousi J, Rinne S, Löfblom J, Orlova A, Deyev S, Tolmachev V.

Int J Oncol. 2019 Apr;54(4):1209-1220. doi: 10.3892/ijo.2019.4712. Epub 2019 Feb 11.

5.

Differential Targeting of c-Maf, Bach-1, and Elmo-1 by microRNA-143 and microRNA-365 Promotes the Intracellular Growth of Mycobacterium tuberculosis in Alternatively IL-4/IL-13 Activated Macrophages.

Tamgue O, Gcanga L, Ozturk M, Whitehead L, Pillay S, Jacobs R, Roy S, Schmeier S, Davids M, Medvedeva YA, Dheda K, Suzuki H, Brombacher F, Guler R.

Front Immunol. 2019 Mar 19;10:421. doi: 10.3389/fimmu.2019.00421. eCollection 2019.

6.

Transcriptionally induced enhancers in the macrophage immune response to Mycobacterium tuberculosis infection.

Denisenko E, Guler R, Mhlanga M, Suzuki H, Brombacher F, Schmeier S.

BMC Genomics. 2019 Jan 22;20(1):71. doi: 10.1186/s12864-019-5450-6.

7.

Comparative Evaluation of Two DARPin Variants: Effect of Affinity, Size, and Label on Tumor Targeting Properties.

Deyev S, Vorobyeva A, Schulga A, Proshkina G, Güler R, Löfblom J, Mitran B, Garousi J, Altai M, Buijs J, Chernov V, Orlova A, Tolmachev V.

Mol Pharm. 2019 Mar 4;16(3):995-1008. doi: 10.1021/acs.molpharmaceut.8b00922. Epub 2019 Feb 8.

PMID:
30608701
8.

Batf2 differentially regulates tissue immunopathology in Type 1 and Type 2 diseases.

Guler R, Mpotje T, Ozturk M, Nono JK, Parihar SP, Chia JE, Abdel Aziz N, Hlaka L, Kumar S, Roy S, Penn-Nicholson A, Hanekom WA, Zak DE, Scriba TJ, Suzuki H, Brombacher F.

Mucosal Immunol. 2019 Mar;12(2):390-402. doi: 10.1038/s41385-018-0108-2. Epub 2018 Dec 12.

PMID:
30542107
9.

Statins: a viable candidate for host-directed therapy against infectious diseases.

Parihar SP, Guler R, Brombacher F.

Nat Rev Immunol. 2019 Feb;19(2):104-117. doi: 10.1038/s41577-018-0094-3. Review.

PMID:
30487528
10.

Deletion of Interleukin-4 Receptor Alpha-Responsive Keratinocytes in BALB/c Mice Does Not Alter Susceptibility to Cutaneous Leishmaniasis.

Govender M, Hurdayal R, Martinez-Salazar B, Gqada K, Pillay S, Gcanga L, Passelli K, Nieuwenhuizen NE, Tacchini-Cottier F, Guler R, Brombacher F.

Infect Immun. 2018 Nov 20;86(12). pii: e00710-18. doi: 10.1128/IAI.00710-18. Print 2018 Dec.

11.

Radionuclide imaging of VEGFR2 in glioma vasculature using biparatopic affibody conjugate: proof-of-principle in a murine model.

Mitran B, Güler R, Roche FP, Lindström E, Selvaraju RK, Fleetwood F, Rinne SS, Claesson-Welsh L, Tolmachev V, Ståhl S, Orlova A, Löfblom J.

Theranostics. 2018 Aug 7;8(16):4462-4476. doi: 10.7150/thno.24395. eCollection 2018.

12.

Transcriptional landscape of Mycobacterium tuberculosis infection in macrophages.

Roy S, Schmeier S, Kaczkowski B, Arner E, Alam T, Ozturk M, Tamgue O, Parihar SP, Kawaji H, Itoh M, Lassmann T, Carninci P, Hayashizaki Y, Forrest ARR, Guler R, Bajic VB, Brombacher F, Suzuki H.

Sci Rep. 2018 Apr 30;8(1):6758. doi: 10.1038/s41598-018-24509-6.

13.

Protein kinase C-delta (PKCδ), a marker of inflammation and tuberculosis disease progression in humans, is important for optimal macrophage killing effector functions and survival in mice.

Parihar SP, Ozturk M, Marakalala MJ, Loots DT, Hurdayal R, Beukes D, Van Reenen M, Zak DE, Mbandi SK, Darboe F, Penn-Nicholson A, Hanekom WA, Leitges M, Scriba TJ, Guler R, Brombacher F.

Mucosal Immunol. 2018 Mar;11(2):579-580. doi: 10.1038/mi.2017.108. Epub 2017 Dec 20.

PMID:
29346346
14.

IL-4Rα Signaling in Keratinocytes and Early IL-4 Production Are Dispensable for Generating a Curative T Helper 1 Response in Leishmania major-Infected C57BL/6 Mice.

Descatoire M, Hurrell BP, Govender M, Passelli K, Martinez-Salazar B, Hurdayal R, Brombacher F, Guler R, Tacchini-Cottier F.

Front Immunol. 2017 Oct 10;8:1265. doi: 10.3389/fimmu.2017.01265. eCollection 2017.

15.

Genome-wide profiling of transcribed enhancers during macrophage activation.

Denisenko E, Guler R, Mhlanga MM, Suzuki H, Brombacher F, Schmeier S.

Epigenetics Chromatin. 2017 Oct 23;10(1):50. doi: 10.1186/s13072-017-0158-9.

16.

Evaluation of minor groove binders (MGBs) as novel anti-mycobacterial agents and the effect of using non-ionic surfactant vesicles as a delivery system to improve their efficacy.

Hlaka L, Rosslee MJ, Ozturk M, Kumar S, Parihar SP, Brombacher F, Khalaf AI, Carter KC, Scott FJ, Suckling CJ, Guler R.

J Antimicrob Chemother. 2017 Dec 1;72(12):3334-3341. doi: 10.1093/jac/dkx326.

17.

FANTOM5 CAGE profiles of human and mouse samples.

Noguchi S, Arakawa T, Fukuda S, Furuno M, Hasegawa A, Hori F, Ishikawa-Kato S, Kaida K, Kaiho A, Kanamori-Katayama M, Kawashima T, Kojima M, Kubosaki A, Manabe RI, Murata M, Nagao-Sato S, Nakazato K, Ninomiya N, Nishiyori-Sueki H, Noma S, Saijyo E, Saka A, Sakai M, Simon C, Suzuki N, Tagami M, Watanabe S, Yoshida S, Arner P, Axton RA, Babina M, Baillie JK, Barnett TC, Beckhouse AG, Blumenthal A, Bodega B, Bonetti A, Briggs J, Brombacher F, Carlisle AJ, Clevers HC, Davis CA, Detmar M, Dohi T, Edge ASB, Edinger M, Ehrlund A, Ekwall K, Endoh M, Enomoto H, Eslami A, Fagiolini M, Fairbairn L, Farach-Carson MC, Faulkner GJ, Ferrai C, Fisher ME, Forrester LM, Fujita R, Furusawa JI, Geijtenbeek TB, Gingeras T, Goldowitz D, Guhl S, Guler R, Gustincich S, Ha TJ, Hamaguchi M, Hara M, Hasegawa Y, Herlyn M, Heutink P, Hitchens KJ, Hume DA, Ikawa T, Ishizu Y, Kai C, Kawamoto H, Kawamura YI, Kempfle JS, Kenna TJ, Kere J, Khachigian LM, Kitamura T, Klein S, Klinken SP, Knox AJ, Kojima S, Koseki H, Koyasu S, Lee W, Lennartsson A, Mackay-Sim A, Mejhert N, Mizuno Y, Morikawa H, Morimoto M, Moro K, Morris KJ, Motohashi H, Mummery CL, Nakachi Y, Nakahara F, Nakamura T, Nakamura Y, Nozaki T, Ogishima S, Ohkura N, Ohno H, Ohshima M, Okada-Hatakeyama M, Okazaki Y, Orlando V, Ovchinnikov DA, Passier R, Patrikakis M, Pombo A, Pradhan-Bhatt S, Qin XY, Rehli M, Rizzu P, Roy S, Sajantila A, Sakaguchi S, Sato H, Satoh H, Savvi S, Saxena A, Schmidl C, Schneider C, Schulze-Tanzil GG, Schwegmann A, Sheng G, Shin JW, Sugiyama D, Sugiyama T, Summers KM, Takahashi N, Takai J, Tanaka H, Tatsukawa H, Tomoiu A, Toyoda H, van de Wetering M, van den Berg LM, Verardo R, Vijayan D, Wells CA, Winteringham LN, Wolvetang E, Yamaguchi Y, Yamamoto M, Yanagi-Mizuochi C, Yoneda M, Yonekura Y, Zhang PG, Zucchelli S, Abugessaisa I, Arner E, Harshbarger J, Kondo A, Lassmann T, Lizio M, Sahin S, Sengstag T, Severin J, Shimoji H, Suzuki M, Suzuki H, Kawai J, Kondo N, Itoh M, Daub CO, Kasukawa T, Kawaji H, Carninci P, Forrest ARR, Hayashizaki Y.

Sci Data. 2017 Aug 29;4:170112. doi: 10.1038/sdata.2017.112.

18.

Protein kinase C-delta (PKCδ), a marker of inflammation and tuberculosis disease progression in humans, is important for optimal macrophage killing effector functions and survival in mice.

Parihar SP, Ozturk M, Marakalala MJ, Loots DT, Hurdayal R, Maasdorp DB, Van Reenen M, Zak DE, Darboe F, Penn-Nicholson A, Hanekom WA, Leitges M, Scriba TJ, Guler R, Brombacher F.

Mucosal Immunol. 2018 Mar;11(2):496-511. doi: 10.1038/mi.2017.68. Epub 2017 Aug 9. Erratum in: Mucosal Immunol. 2017 Dec 20;:.

PMID:
28832027
19.

An evaluation of Minor Groove Binders as anti-fungal and anti-mycobacterial therapeutics.

Scott FJ, Nichol RJO, Khalaf AI, Giordani F, Gillingwater K, Ramu S, Elliott A, Zuegg J, Duffy P, Rosslee MJ, Hlaka L, Kumar S, Ozturk M, Brombacher F, Barrett M, Guler R, Suckling CJ.

Eur J Med Chem. 2017 Aug 18;136:561-572. doi: 10.1016/j.ejmech.2017.05.039. Epub 2017 May 17.

PMID:
28544982
20.

IRNdb: the database of immunologically relevant non-coding RNAs.

Denisenko E, Ho D, Tamgue O, Ozturk M, Suzuki H, Brombacher F, Guler R, Schmeier S.

Database (Oxford). 2016 Oct 25;2016. pii: baw138. doi: 10.1093/database/baw138.

21.

Topical Simvastatin as Host-Directed Therapy against Severity of Cutaneous Leishmaniasis in Mice.

Parihar SP, Hartley MA, Hurdayal R, Guler R, Brombacher F.

Sci Rep. 2016 Sep 16;6:33458. doi: 10.1038/srep33458.

22.

Evaluation of the Effect of Bosentan-Mediated Endothelin Receptor Blockade on Flap Survival in Rats: An Experimental Study.

Görgülü T, Guler R, Olgun A, Torun M, Kargi E.

Facial Plast Surg. 2016 Aug;32(4):431-7. doi: 10.1055/s-0036-1584948. Epub 2016 Aug 5.

PMID:
27494588
23.

Novel affinity binders for neutralization of vascular endothelial growth factor (VEGF) signaling.

Fleetwood F, Güler R, Gordon E, Ståhl S, Claesson-Welsh L, Löfblom J.

Cell Mol Life Sci. 2016 Apr;73(8):1671-83. doi: 10.1007/s00018-015-2088-7. Epub 2015 Nov 9.

PMID:
26552422
24.

Host-directed drug therapy for tuberculosis.

Guler R, Brombacher F.

Nat Chem Biol. 2015 Oct;11(10):748-51. doi: 10.1038/nchembio.1917. No abstract available.

PMID:
26379013
25.

Targeting Batf2 for infectious diseases and cancer.

Guler R, Roy S, Suzuki H, Brombacher F.

Oncotarget. 2015 Sep 29;6(29):26575-82. doi: 10.18632/oncotarget.5576.

26.

Redefining the transcriptional regulatory dynamics of classically and alternatively activated macrophages by deepCAGE transcriptomics.

Roy S, Schmeier S, Arner E, Alam T, Parihar SP, Ozturk M, Tamgue O, Kawaji H, de Hoon MJ, Itoh M, Lassmann T, Carninci P, Hayashizaki Y, Forrest AR, Bajic VB, Guler R; Fantom Consortium, Brombacher F, Suzuki H.

Nucleic Acids Res. 2015 Aug 18;43(14):6969-82. doi: 10.1093/nar/gkv646. Epub 2015 Jun 27.

27.

Fast and Painless Skin Tag Excision with Ethyl Chloride.

Görgülü T, Torun M, Güler R, Olgun A, Kargi E.

Aesthetic Plast Surg. 2015 Aug;39(4):644-5. doi: 10.1007/s00266-015-0508-6. Epub 2015 Jun 5.

PMID:
26044394
28.

Batf2/Irf1 induces inflammatory responses in classically activated macrophages, lipopolysaccharides, and mycobacterial infection.

Roy S, Guler R, Parihar SP, Schmeier S, Kaczkowski B, Nishimura H, Shin JW, Negishi Y, Ozturk M, Hurdayal R, Kubosaki A, Kimura Y, de Hoon MJ, Hayashizaki Y, Brombacher F, Suzuki H.

J Immunol. 2015 Jun 15;194(12):6035-44. doi: 10.4049/jimmunol.1402521. Epub 2015 May 8.

29.

IL-4Rα-dependent alternative activation of macrophages is not decisive for Mycobacterium tuberculosis pathology and bacterial burden in mice.

Guler R, Parihar SP, Savvi S, Logan E, Schwegmann A, Roy S, Nieuwenhuizen NE, Ozturk M, Schmeier S, Suzuki H, Brombacher F.

PLoS One. 2015 Mar 19;10(3):e0121070. doi: 10.1371/journal.pone.0121070. eCollection 2015.

30.

Transcribed enhancers lead waves of coordinated transcription in transitioning mammalian cells.

Arner E, Daub CO, Vitting-Seerup K, Andersson R, Lilje B, Drabløs F, Lennartsson A, Rönnerblad M, Hrydziuszko O, Vitezic M, Freeman TC, Alhendi AM, Arner P, Axton R, Baillie JK, Beckhouse A, Bodega B, Briggs J, Brombacher F, Davis M, Detmar M, Ehrlund A, Endoh M, Eslami A, Fagiolini M, Fairbairn L, Faulkner GJ, Ferrai C, Fisher ME, Forrester L, Goldowitz D, Guler R, Ha T, Hara M, Herlyn M, Ikawa T, Kai C, Kawamoto H, Khachigian LM, Klinken SP, Kojima S, Koseki H, Klein S, Mejhert N, Miyaguchi K, Mizuno Y, Morimoto M, Morris KJ, Mummery C, Nakachi Y, Ogishima S, Okada-Hatakeyama M, Okazaki Y, Orlando V, Ovchinnikov D, Passier R, Patrikakis M, Pombo A, Qin XY, Roy S, Sato H, Savvi S, Saxena A, Schwegmann A, Sugiyama D, Swoboda R, Tanaka H, Tomoiu A, Winteringham LN, Wolvetang E, Yanagi-Mizuochi C, Yoneda M, Zabierowski S, Zhang P, Abugessaisa I, Bertin N, Diehl AD, Fukuda S, Furuno M, Harshbarger J, Hasegawa A, Hori F, Ishikawa-Kato S, Ishizu Y, Itoh M, Kawashima T, Kojima M, Kondo N, Lizio M, Meehan TF, Mungall CJ, Murata M, Nishiyori-Sueki H, Sahin S, Nagao-Sato S, Severin J, de Hoon MJ, Kawai J, Kasukawa T, Lassmann T, Suzuki H, Kawaji H, Summers KM, Wells C; FANTOM Consortium, Hume DA, Forrest AR, Sandelin A, Carninci P, Hayashizaki Y.

Science. 2015 Feb 27;347(6225):1010-4. doi: 10.1126/science.1259418. Epub 2015 Feb 12.

31.

A promoter-level mammalian expression atlas.

FANTOM Consortium and the RIKEN PMI and CLST (DGT), Forrest AR, Kawaji H, Rehli M, Baillie JK, de Hoon MJ, Haberle V, Lassmann T, Kulakovskiy IV, Lizio M, Itoh M, Andersson R, Mungall CJ, Meehan TF, Schmeier S, Bertin N, Jørgensen M, Dimont E, Arner E, Schmidl C, Schaefer U, Medvedeva YA, Plessy C, Vitezic M, Severin J, Semple C, Ishizu Y, Young RS, Francescatto M, Alam I, Albanese D, Altschuler GM, Arakawa T, Archer JA, Arner P, Babina M, Rennie S, Balwierz PJ, Beckhouse AG, Pradhan-Bhatt S, Blake JA, Blumenthal A, Bodega B, Bonetti A, Briggs J, Brombacher F, Burroughs AM, Califano A, Cannistraci CV, Carbajo D, Chen Y, Chierici M, Ciani Y, Clevers HC, Dalla E, Davis CA, Detmar M, Diehl AD, Dohi T, Drabløs F, Edge AS, Edinger M, Ekwall K, Endoh M, Enomoto H, Fagiolini M, Fairbairn L, Fang H, Farach-Carson MC, Faulkner GJ, Favorov AV, Fisher ME, Frith MC, Fujita R, Fukuda S, Furlanello C, Furino M, Furusawa J, Geijtenbeek TB, Gibson AP, Gingeras T, Goldowitz D, Gough J, Guhl S, Guler R, Gustincich S, Ha TJ, Hamaguchi M, Hara M, Harbers M, Harshbarger J, Hasegawa A, Hasegawa Y, Hashimoto T, Herlyn M, Hitchens KJ, Ho Sui SJ, Hofmann OM, Hoof I, Hori F, Huminiecki L, Iida K, Ikawa T, Jankovic BR, Jia H, Joshi A, Jurman G, Kaczkowski B, Kai C, Kaida K, Kaiho A, Kajiyama K, Kanamori-Katayama M, Kasianov AS, Kasukawa T, Katayama S, Kato S, Kawaguchi S, Kawamoto H, Kawamura YI, Kawashima T, Kempfle JS, Kenna TJ, Kere J, Khachigian LM, Kitamura T, Klinken SP, Knox AJ, Kojima M, Kojima S, Kondo N, Koseki H, Koyasu S, Krampitz S, Kubosaki A, Kwon AT, Laros JF, Lee W, Lennartsson A, Li K, Lilje B, Lipovich L, Mackay-Sim A, Manabe R, Mar JC, Marchand B, Mathelier A, Mejhert N, Meynert A, Mizuno Y, de Lima Morais DA, Morikawa H, Morimoto M, Moro K, Motakis E, Motohashi H, Mummery CL, Murata M, Nagao-Sato S, Nakachi Y, Nakahara F, Nakamura T, Nakamura Y, Nakazato K, van Nimwegen E, Ninomiya N, Nishiyori H, Noma S, Noma S, Noazaki T, Ogishima S, Ohkura N, Ohimiya H, Ohno H, Ohshima M, Okada-Hatakeyama M, Okazaki Y, Orlando V, Ovchinnikov DA, Pain A, Passier R, Patrikakis M, Persson H, Piazza S, Prendergast JG, Rackham OJ, Ramilowski JA, Rashid M, Ravasi T, Rizzu P, Roncador M, Roy S, Rye MB, Saijyo E, Sajantila A, Saka A, Sakaguchi S, Sakai M, Sato H, Savvi S, Saxena A, Schneider C, Schultes EA, Schulze-Tanzil GG, Schwegmann A, Sengstag T, Sheng G, Shimoji H, Shimoni Y, Shin JW, Simon C, Sugiyama D, Sugiyama T, Suzuki M, Suzuki N, Swoboda RK, 't Hoen PA, Tagami M, Takahashi N, Takai J, Tanaka H, Tatsukawa H, Tatum Z, Thompson M, Toyodo H, Toyoda T, Valen E, van de Wetering M, van den Berg LM, Verado R, Vijayan D, Vorontsov IE, Wasserman WW, Watanabe S, Wells CA, Winteringham LN, Wolvetang E, Wood EJ, Yamaguchi Y, Yamamoto M, Yoneda M, Yonekura Y, Yoshida S, Zabierowski SE, Zhang PG, Zhao X, Zucchelli S, Summers KM, Suzuki H, Daub CO, Kawai J, Heutink P, Hide W, Freeman TC, Lenhard B, Bajic VB, Taylor MS, Makeev VJ, Sandelin A, Hume DA, Carninci P, Hayashizaki Y.

Nature. 2014 Mar 27;507(7493):462-70. doi: 10.1038/nature13182.

32.

Preclinical efficacy and safety of an anti-IL-1β vaccine for the treatment of type 2 diabetes.

Spohn G, Schori C, Keller I, Sladko K, Sina C, Guler R, Schwarz K, Johansen P, Jennings GT, Bachmann MF.

Mol Ther Methods Clin Dev. 2014 Oct 22;1:14048. doi: 10.1038/mtm.2014.48. eCollection 2014.

33.

Statin therapy reduces the mycobacterium tuberculosis burden in human macrophages and in mice by enhancing autophagy and phagosome maturation.

Parihar SP, Guler R, Khutlang R, Lang DM, Hurdayal R, Mhlanga MM, Suzuki H, Marais AD, Brombacher F.

J Infect Dis. 2014 Mar 1;209(5):754-63. doi: 10.1093/infdis/jit550. Epub 2013 Oct 16.

PMID:
24133190
34.

Simvastatin enhances protection against Listeria monocytogenes infection in mice by counteracting Listeria-induced phagosomal escape.

Parihar SP, Guler R, Lang DM, Suzuki H, Marais AD, Brombacher F.

PLoS One. 2013 Sep 24;8(9):e75490. doi: 10.1371/journal.pone.0075490. eCollection 2013.

35.

The C-type lectin receptor CLECSF8 (CLEC4D) is expressed by myeloid cells and triggers cellular activation through Syk kinase.

Graham LM, Gupta V, Schafer G, Reid DM, Kimberg M, Dennehy KM, Hornsell WG, Guler R, Campanero-Rhodes MA, Palma AS, Feizi T, Kim SK, Sobieszczuk P, Willment JA, Brown GD.

J Biol Chem. 2012 Jul 27;287(31):25964-74. doi: 10.1074/jbc.M112.384164. Epub 2012 Jun 11.

36.

Syk kinase-coupled C-type lectin receptors engage protein kinase C-σ to elicit Card9 adaptor-mediated innate immunity.

Strasser D, Neumann K, Bergmann H, Marakalala MJ, Guler R, Rojowska A, Hopfner KP, Brombacher F, Urlaub H, Baier G, Brown GD, Leitges M, Ruland J.

Immunity. 2012 Jan 27;36(1):32-42. doi: 10.1016/j.immuni.2011.11.015.

37.

PKCδ regulates IL-12p40/p70 production by macrophages and dendritic cells, driving a type 1 healer phenotype in cutaneous leishmaniasis.

Guler R, Afshar M, Arendse B, Parihar SP, Revaz-Breton M, Leitges M, Schwegmann A, Brombacher F.

Eur J Immunol. 2011 Mar;41(3):706-15. doi: 10.1002/eji.201040985. Epub 2011 Feb 1.

38.

Blocking IL-1α but not IL-1β increases susceptibility to chronic Mycobacterium tuberculosis infection in mice.

Guler R, Parihar SP, Spohn G, Johansen P, Brombacher F, Bachmann MF.

Vaccine. 2011 Feb 1;29(6):1339-46. doi: 10.1016/j.vaccine.2010.10.045. Epub 2010 Nov 18.

PMID:
21093494
39.

The Syk/CARD9-coupled receptor Dectin-1 is not required for host resistance to Mycobacterium tuberculosis in mice.

Marakalala MJ, Guler R, Matika L, Murray G, Jacobs M, Brombacher F, Rothfuchs AG, Sher A, Brown GD.

Microbes Infect. 2011 Feb;13(2):198-201. doi: 10.1016/j.micinf.2010.10.013. Epub 2010 Oct 27.

40.

Limited role for lymphotoxin α in the host immune response to Mycobacterium tuberculosis.

Allie N, Keeton R, Court N, Abel B, Fick L, Vasseur V, Vacher R, Olleros ML, Drutskaya MS, Guler R, Nedospasov SA, Garcia I, Ryffel B, Quesniaux VF, Jacobs M.

J Immunol. 2010 Oct 1;185(7):4292-301. doi: 10.4049/jimmunol.1000650. Epub 2010 Sep 3.

41.

CD28 and IL-4: two heavyweights controlling the balance between immunity and inflammation.

Hünig T, Lühder F, Elflein K, Gogishvili T, Fröhlich M, Guler R, Cutler A, Brombacher F.

Med Microbiol Immunol. 2010 Aug;199(3):239-46. doi: 10.1007/s00430-010-0156-z. Review.

42.

The role of scavenger receptor B1 in infection with Mycobacterium tuberculosis in a murine model.

Schäfer G, Guler R, Murray G, Brombacher F, Brown GD.

PLoS One. 2009 Dec 24;4(12):e8448. doi: 10.1371/journal.pone.0008448.

43.

Protein kinase C delta is essential for optimal macrophage-mediated phagosomal containment of Listeria monocytogenes.

Schwegmann A, Guler R, Cutler AJ, Arendse B, Horsnell WG, Flemming A, Kottmann AH, Ryan G, Hide W, Leitges M, Seoighe C, Brombacher F.

Proc Natl Acad Sci U S A. 2007 Oct 9;104(41):16251-6. Epub 2007 Oct 3.

44.

A virus-like particle-based vaccine selectively targeting soluble TNF-alpha protects from arthritis without inducing reactivation of latent tuberculosis.

Spohn G, Guler R, Johansen P, Keller I, Jacobs M, Beck M, Rohner F, Bauer M, Dietmeier K, Kündig TM, Jennings GT, Brombacher F, Bachmann MF.

J Immunol. 2007 Jun 1;178(11):7450-7.

45.

Loss of calcineurin Aalpha results in altered trafficking of AQP2 and in nephrogenic diabetes insipidus.

Gooch JL, Guler RL, Barnes JL, Toro JJ.

J Cell Sci. 2006 Jun 15;119(Pt 12):2468-76. Epub 2006 May 30.

46.

Monitoring the effects of water pollution on Cyprinus carpio in Karakaya Dam Lake, Turkey.

Ozmen M, Güngördü A, Kucukbay FZ, Güler RE.

Ecotoxicology. 2006 Mar;15(2):157-69. Epub 2005 Dec 23.

PMID:
16374666
47.
48.

Contribution of transmembrane tumor necrosis factor to host defense against Mycobacterium bovis bacillus Calmette-guerin and Mycobacterium tuberculosis infections.

Olleros ML, Guler R, Vesin D, Parapanov R, Marchal G, Martinez-Soria E, Corazza N, Pache JC, Mueller C, Garcia I.

Am J Pathol. 2005 Apr;166(4):1109-20.

49.

Circulating concentrations of interleukin-18, interleukin-18 binding protein, and gamma interferon in patients with alcoholic hepatitis.

Spahr L, Garcia I, Bresson-Hadni S, Rubbia-Brandt L, Guler R, Olleros M, Chvatchko Y, Hadengue A.

Liver Int. 2004 Dec;24(6):582-7.

PMID:
15566508
50.

Inhibition of inducible nitric oxide synthase protects against liver injury induced by mycobacterial infection and endotoxins.

Guler R, Olleros ML, Vesin D, Parapanov R, Vesin C, Kantengwa S, Rubbia-Brandt L, Mensi N, Angelillo-Scherrer A, Martinez-Soria E, Tacchini-Cottier F, Garcia I.

J Hepatol. 2004 Nov;41(5):773-81.

PMID:
15519650

Supplemental Content

Support Center